(NASDAQ: HBIO) Harvard Bioscience's forecast annual revenue growth rate of 0.28% is not forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 5.02%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 1,450.25%.
Harvard Bioscience's revenue in 2025 is $87,371,000.On average, 4 Wall Street analysts forecast HBIO's revenue for 2025 to be $3,905,981,088, with the lowest HBIO revenue forecast at $3,739,698,938, and the highest HBIO revenue forecast at $4,034,905,479.
In 2026, HBIO is forecast to generate $4,187,902,889 in revenue, with the lowest revenue forecast at $3,870,763,153 and the highest revenue forecast at $4,474,906,773.